NASDAQ: PIRS - Pieris Pharmaceuticals, Inc.

Altı ay boyunca karlılık: +58.69%
Sektör: Healthcare

Promosyon programı Pieris Pharmaceuticals, Inc.


Şirket hakkında

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin based drug candidate, elarekibep used for the treatment of asthma; and PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis.

daha fazla ayrıntı
The company also develops PRS-344/S09501 2that consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.

EBITDA -0.0261
EV/EBITDA -4.87
IPO date 2015-04-13
ISIN US7207951036
Industry Biotechnology
P/BV 3.37
P/S 3.74
Sector Health Care
Валюта usd
Валюта отчета usd
Выручка 0.0463
Сайт https://www.pieris.com
Цена ао 0.188
Число акций ао 0.09006 млрд
Günlük fiyat değişimi: 0% (13.6)
Haftalık fiyat değişimi: 0% (13.6)
Aylık fiyat değişimi: -19.19% (16.83)
3 ayda fiyat değişimi: -15.84% (16.16)
Altı ayda fiyat değişimi: +58.69% (8.57)
Yıllık fiyat değişimi: +7 372.53% (0.182)
3 yılda fiyat değişimi: +296.5% (3.43)
5 yılda fiyat değişimi: +242.57% (3.97)
10 yılda fiyat değişimi: 0% (13.6)
Yılbaşından bu yana fiyat değişimi: 0% (13.6)

Hafife alma

İsim Anlam Seviye
P/S 0.3316 10
P/BV 0.5305 10
P/E 0 0
EV/EBITDA 0.2277 10
Toplam: 6.25

Yeterlik

İsim Anlam Seviye
ROA, % -63.45 0
ROE, % -91.72 0
Toplam: 0

Temettüler

İsim Anlam Seviye
Div yield, % 0 0
DSI 0 0
Toplam: 0

Görev

İsim Anlam Seviye
Debt/EBITDA -0.9315 10
Toplam: 9.6

Büyüme dürtüsü

İsim Anlam Seviye
karlılık Revenue, % -7.54 0
karlılık Ebitda, % -12.79 0
karlılık EPS, % 4546.31 10
Toplam: 2.2

Kurumlar Hacim Paylaşmak, %
BVF Inc. 20609863 20.83
Lynx1 Capital Management Lp 9775849 9.88
Citadel Advisors Llc 1189887 1.2
Renaissance Technologies, LLC 1065007 1.08
Blackrock Inc. 1037747 1.05
Acadian Asset Management. LLC 962358 0.97
Vanguard Group Inc 907390 0.92
Geode Capital Management, LLC 761444 0.77
CM Management, LLC 750000 0.76
Northern Trust Corporation 243592 0.25



Süpervizör İş unvanı Ödeme Doğum yılı
Mr. Stephen S. Yoder J.D. CEO, President & Director 744.13k 1976 (49 yıllar)
Mr. Thomas Bures Senior VP, CFO & Treasurer 487.5k 1975 (50 yıllar)
Maria Kelman Executive Director of Investor Relations N/A
Dr. Shane Olwill Ph.D. Senior VP & Chief Development Officer 463.91k 1976 (49 yıllar)
Mr. Prompong Chaikul Chief Supply Chain Officer N/A 1987 (38 yıllar)

Adres: United States, Boston. MA, 225 Franklin Street - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: https://www.pieris.com